Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Small Cell Lung Carcinoma 63Leukemia, Myeloid, Acute 14Carcinoma, Non-Small-Cell Lung 14Lung Neoplasms 11Lymphoma, Non-Hodgkin 9Lymphoma, Large B-Cell, Diffuse 9Recurrence 8Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 6Lymphoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Carcinoma, Small Cell 4Ovarian Neoplasms 3Leukemia 3Hodgkin Disease 3Extensive Stage Small Cell Lung Cancer 3Small Cell Lung Cancer Extensive Stage 2SCLC 2Osteosarcoma 2Neoplasm Metastasis 2Lymphoma, B-Cell 2Lymphatic Diseases 2Immunoproliferative Disorders 2Hematologic Diseases 2Glioblastoma 2Ependymoma 2Advanced Solid Tumors 2Widespread Small Cell Lung Cancer 1Unresectable Locally Advanced or Metastatic Solid Tumors 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

tislelizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1olaparib 1Topotecan 1Sirolimus 1SAR125844 1Injections 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Malignant Solid Tumors × Etoposide × Clear all
NCT07268040 2026-01-12

A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 2 Recruiting
400 enrolled
Other solid neoplasm

Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡